Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in
Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q)
Myelodysplastic Syndrome (MDS).